. 2021 Aug 7;2021(3):hoab030. doi: 10.1093/hropen/hoab030

Table I.

Study characteristics and types of intervention of the included studies.

Author, year	Country	Inclusion period	Study design	n, total (n per arm)	Diagnostic tool	Intervention group 1
						Intervention group 2
						Intervention group 3
Kwack et al., 2021	Korea	May 2011–May 2019	Cohort, retrospective	22	MRI	Adenomyomectomy, antenatal follow-up with strict protocol
Sun et al., 2021	China	January 2015–July 2018	Cohort, not reported if prospective or retrospective	52	MRI	Laparoscopic adenomyomectomy + insertion of LNG IUS
Sun et al., 2020	China	June 2012–August 2014	Cohort, not reported if prospective or retrospective	90	TVUS + MRI + Ca125	‘Major uterine wall resection and reconstruction of the uterus’ (MURU) + LNG-IUS
Lin et al., 2020	China	October 2015–October 2017	Prospective randomized parallel controlled trial	133 (68/65)	Ultrasound + MRI	Transcutaneous microwave ablation
Lin et al., 2020	China	October 2015–October 2017	Prospective randomized parallel controlled trial	133 (68/65)	Ultrasound + MRI	Percutaneous radiofrequency ablation
Li et al., 2020	China	January 2012–January 2017	Retrospective open, non-randomized, controlled trial	193 (57/83/53)	TVUS	Open adenomyomectomy
						Open adenomyomectomy + 6 months GnRH-a
						Open adenomyomectomy + 6 months GnRH-a + LNG IUS
Huang et al., 2020	China	January 2012–January 2017	Retrospective non-randomized controlled trial	93 (50/43)	TVUS	HIFU + GnRH-a for 4–6 months
Huang et al., 2020	China	January 2012–January 2017	Retrospective non-randomized controlled trial	93 (50/43)	TVUS	Adenomyomectomy + GnRH-a for 4–6 months
Yang et al., 2019	China	August 2015–November 2017	Cohort prospective	466	MRI + TVUS	HIFU + GnRH-a for 3 months + LNG IUS
Lee et al., 2019	Korea	February 2010–October 2017	Cohort retrospective	889	MRI + TVUS	HIFU
Jun-Min et al., 2018	China	January 2012–December 2014	Cohort, retrospective	198	MRI + TVUS	U-shaped myometrial excavation and modified suture approach
Li et al., 2018	China	February 2015–February 2016	Prospective, nonrandomized, parallel-controlled study	200 (40/40/40/40/20/20)	TVUS	Group 1: 3.75 mg GnRH-a	Group 2: 1.88 mg GnRH-a	Group 3: LNG IUS
Li et al., 2018	China	February 2015–February 2016	Prospective, nonrandomized, parallel-controlled study	200 (40/40/40/40/20/20)	TVUS	Group 4: 3.75 mg GnRH-a + LNG IUS	Group 5: 1.88 mg GnRH-a + LNG IUS	Group 6: San-Jie-Zhen-Tong capsules
Guo et al., 2018	China	January 2013–January 2015	Cohort retrospective	78 (45/15/18)	MRI + TVUS	HIFU only
						HIFU + LNG IUS
						HIFU + GnRH-a
Alizzi, 2018	Iraq	January 2016–January 2018	Cohort prospective	32	TVUS + clinical symptoms	GnRH-a every 28 days until uterine volume <150 cm, then LNG IUS.
Yang et al., 2017	China	January 2019–December 2013	Cohort prospective	112 (56/56)	TVUS and/or MRI	Laparoscopic uterine artery occlusion and partial adenomyomectomy + laparoscopic uterine pelvic plexus ablation
Yang et al., 2017	China	January 2019–December 2013	Cohort prospective	112 (56/56)	TVUS and/or MRI	Laparoscopic uterine artery occlusion and partial adenomyomectomy only
Osuga et al., 2017	Japan	August 2014–June 2015	Randomized, double-blind, multicentre, placebo-controlled phase III study	68 (35/33)	TVUS + MRI	Dienogest twice daily for 16 weeks, starting between the second and fifth day of the menstrual cycle, analgetic if needed
Osuga et al., 2017	Japan	August 2014–June 2015		68 (35/33)	TVUS + MRI	Placebo twice daily for 16 weeks, starting between the second and fifth day of the menstrual cycle, analgetic if needed
Liu et al., 2017	China	January 2012–December 2016	Cohort retrospective	368 (66/302)	TVUS or MRI	HIFU
Liu et al., 2017	China	January 2012–December 2016	Cohort retrospective	368 (66/302)	TVUS or MRI	Abdominal hysterectomy
Huang et al., 2017	China	January 2011–August 2015	Cohort retrospective	102	MRI	MR-HIFU alone
Huang et al., 2017	China	January 2011–August 2015	Cohort retrospective	102	MRI	MR HIFU + exercise
Hai et al., 2017	China	January 2013–October 2015	Cohort retrospective	87	MRI + TVUS + biopsy in some	Ultrasound-guided transcervical radiofrequency ablation
Park et al., 2016	Korea	February 2010–December 2014	Cohort retrospective	192	TVUS	HIFU
Liu et al., 2016	China	January 2007–December 2013	Cohort retrospective	230	MRI	HIFU
Chong et al., 2016	Korea	August 2008–May 2011	Cohort prospective	33	TVUS + MRI	Laparoscopic or robotic adenomyomectomy with uterine artery ligation
Chong et al., 2016	Korea	August 2008–May 2011	Cohort prospective	33	TVUS + MRI	N = 18 (random) GnRH-a additionally
Long et al. 2015	China	January 2012–December 2012	Cohort prospective	51	MRI	HIFU
Lee et al., 2015	Korea	February 2010–October 2013	Cohort retrospective	346	TVUS + MRI	HIFU
Huang et al., 2015	China	March 2011–February 2014	Cohort prospective (patient chose group)	94 (48/46)	MRI + TVUS	Adenomyomectomy, conventional + 6 months GnRH-a
Huang et al., 2015	China	March 2011–February 2014	Cohort prospective (patient chose group)	94 (48/46)	MRI + TVUS	Adenomyomectomy double flap + 6 months GnRH-a
Zhang et al., 2014	China	November 2010–June 2012	RCT	86 (43/43)	MRI	HIFU + oxytocin injection during HIFU ablation procedure
Zhang et al., 2014	China	November 2010–June 2012	RCT	86 (43/43)	MRI	HIFU + 0.9% saline injection
Liu et al., 2014	China	July 2003–July 2009	Retrospective cohort	182	TVUS	Bilateral laparoscopic uterine artery occlusion + adenomyomectomy
Ekin et al., 2013	Turkey	January 2012–December 2012	Cohort prospective	70	TVUS	LNG IUS
Kelekci et al., 2012	Turkey	March 2006–May 2009	Prospective, open, nonrandomized	74 (23/25/26)	TVUS	LNG IUS (patients with adenomyosis)
						LNG IUS (patients without adenomyosis)
						Copper intrauterine device (patients without adenomyosis)
Zhou et al., 2011	China	March 2007–September 2008	Cohort prospective	78	MRI	HIFU
Ozdegirmenci et al., 2011	Turkey	April 2007–February 2009	RCT	75 (43/32)	TVUS + MRI	LNG IUS
Ozdegirmenci et al., 2011	Turkey	April 2007–February 2009	RCT	75 (43/32)	TVUS + MRI	Abdominal hysterectomy
Kang et al., 2010	China	January 2005–June 2007	Randomized prospective observational	70	MRI or TVUS	‘4-dose regimen’ (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses)
Kang et al., 2010	China	January 2005–June 2007	Randomized prospective observational	70	MRI or TVUS	Conventional regimen (1 injection every 4 weeks for a total of 6 doses).
Sheng et al., 2009	China	NR	Prospective cohort	94	TVUS	LNG IUS
Kang et al., 2009	China	July 2003–October 2005	Retrospective cohort study	37	TVUS + clinical symptoms	Laparoscopic adenomyosis resection + uterine artery occlusion
Cho et al., 2008	Korea	July 2003–March 2007	Cohort prospective	47	TVUS	LNG IUS
Kim et al., 2007	Korea	1998–2000	Cohort prospective	54	MRI	Uterine artery embolization
Bragheto et al., 2007	Brazil	NR	Cohort prospective	29	MRI	LNG IUS
Hadisaputra and Anggraeni, 2006	Indonesia	June 2003–June 2004	Randomized controlled trial	20 (10/10)	TVUS	Laparoscopic resection + GnRH-a for 3 months
Hadisaputra and Anggraeni, 2006	Indonesia	June 2003–June 2004	Randomized controlled trial	20 (10/10)	TVUS	Laparoscopic myolysis + GnRH-a for 3 months
Maia et al., 2003	Brazil	NR	Cohort retrospective	95 (53/42)	TVUS	Transcervical endometrial resection + LNG IUS
Maia et al., 2003	Brazil	NR	Cohort retrospective	95 (53/42)	TVUS	Transcervical endometrial resection
Fedele et al., 1997	Italy	NR	Cohort prospective	25	TVUS or MRI	LNG IUS

GnRH-a, gonadotropin-releasing hormone analogue; HIFU, high-intensity focused ultrasound; LNG IUS, levonorgestrel-releasing intrauterine system; TVUS, transvaginal ultrasound.